human kras mutant crc cell line hct116 (ATCC)
ATCC is a verified supplier 
ATCC manufactures this product 
99
Structured Review
ATCC
human kras mutant crc cell line hct116
Human Kras Mutant Crc Cell Line Hct116, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 4085 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+kras+mutant+crc+cell+line+hct116/HCT+116/pm25389372-210-1-11
Average 99 stars, based on 4085 article reviews
Human Kras Mutant Crc Cell Line Hct116, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 4085 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+kras+mutant+crc+cell+line+hct116/HCT+116/pm25389372-210-1-11
Average 99 stars, based on 4085 article reviews
human kras mutant crc cell line hct116 - by Bioz Stars,
2026-10
99/100 stars
Images
Related Articles
other:Article Title: Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR. Article Snippet: http:/e.sciencem agorg/ D ow nladed from Targeted blockade of aberrantly activated signaling pathways is an attractive therapeutic strategy for solid tumors, but drug resistance is common.. KRAS is a frequently mutated gene in human cancer but remains a challenging clinical target.. Inhibitors against KRAS signaling mediators, namely, PI3K (phosphatidylinositol 3-kinase) and mTOR (mechanistic target of rapamycin), have limited clinical efficacy as single agents in KRAS-mutant colorectal cancer (CRC). |